Literature DB >> 9037360

Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas.

E Zucca1, F Bertoni, G Bosshard, E Roggero, E Ceresa, P Sanna, E Pedrinis, F Cavalli.   

Abstract

BACKGROUND: Approximately one-fourth of diffuse large B-cell lymphomas (DLCL) carry the bcl-2(MBR)/JH rearrangement caused by the t(14;18) translocation. The clinical significance of this rearrangement in patients with DLCL remains controversial. By polymerase chain reaction (PCR) we prospectively evaluated the prognostic relevance of the bcl-2 (MBR)/JH rearrangement present in circulating B-cells at the time of diagnosis.
MATERIALS AND METHODS: The bcl-2 (MBR)/JH rearrangement was analysed by a nested-PCR method in peripheral blood samples of 51 HIV-negative patients with previously untreated DLCL.
RESULTS: The bcl-2 (MBR)/JH rearrangement was detected in 16 cases (31%). Peripheral blood bcl-2 (MBR)/JH rearrangement detection by PCR at diagnosis was correlated with poor overall survival, lymphoma-specific survival and time to progression (log-rank P < 0.05). There was no statistically significant difference between the clinical characteristics at presentation of bcl-2/JH-positive and negative patients.
CONCLUSIONS: The peripheral blood is a readily accessible tissue for this type of analysis, and this study indicates that detection of the t(14;18) translocation at presentation in the blood of patients with DLCL may presage a poor prognosis.

Entities:  

Mesh:

Year:  1996        PMID: 9037360     DOI: 10.1093/oxfordjournals.annonc.a010494

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

1.  Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

Authors:  Lawrence D Kaplan; Jeannette Y Lee; Richard F Ambinder; Joseph A Sparano; Ethel Cesarman; Amy Chadburn; Alexandra M Levine; David T Scadden
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 2.  Genetic lesions in diffuse large B-cell lymphomas.

Authors:  M Testoni; E Zucca; K H Young; F Bertoni
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.